Inactive Instrument

GEMI THER

Equities

GMTX

US36870G1058

Gemini Therapeutics, Inc. Reports Earnings Results for the Year Ended December 31, 2020

March 30, 2021 at 02:00 am IST

Gemini Therapeutics, Inc. reported earnings results for the year ended December 31, 2020. For the year, the company reported net loss of $40.8 million compared to $41.4 million for the same period in 2019.

Latest news about GEMI THER

Arix portfolio firm Disc Medicine seals Gemini Therapeutics merger	30/22/30	AN
Gemini Therapeutics, Inc.(NasdaqGM:GMTX) dropped from NASDAQ Composite Index	29/22/29	CI
Disc Medicine, Inc. completed the acquisition of Gemini Therapeutics, Inc. for approximately $200 million in a reverse merger transaction.	29/22/29	CI
Gemini Therapeutics Shares Rise After Disc Medicine Gets FDA Designation	27/22/27	DJ
Gemini Therapeutics' Disc Medicine Secures FDA's Orphan Drug Status for Erythropoietic Protoporphyria Treatment	23/22/23	MT
Gemini Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/22/10	CI
Gemini Therapeutics, Inc.(NasdaqGM:GMTX) dropped from S&P Global BMI Index	19/22/19	CI
Gemini Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	11/22/11	CI
Arix Bioscience To Invest $54 Million To Fund All-stock Disc Medicine, Gemini Therapeutics Merger	11/22/11	MT
Gemini Therapeutics Merges With Disc Medicine	10/22/10	MT
Disc Medicine, Inc. entered into an agreement to acquire Gemini Therapeutics, Inc. in a reverse merger transaction.	10/22/10	CI
Gemini Therapeutics, Inc.(NasdaqGM:GMTX) dropped from Russell 2000 Defensive Index	24/22/24	CI
Gemini Therapeutics, Inc.(NasdaqGM:GMTX) dropped from Russell Microcap Growth Index	24/22/24	CI
Gemini Therapeutics, Inc.(NasdaqGM:GMTX) dropped from Russell 3000E Value Index	24/22/24	CI
Gemini Therapeutics, Inc.(NasdaqGM:GMTX) dropped from Russell 3000 Value Index	24/22/24	CI
Gemini Therapeutics, Inc.(NasdaqGM:GMTX) dropped from Russell Small Cap Completeness Index	24/22/24	CI
Gemini Therapeutics, Inc.(NasdaqGM:GMTX) dropped from Russell 3000 Index	24/22/24	CI
Gemini Therapeutics, Inc.(NasdaqGM:GMTX) dropped from Russell 2000 Value-Defensive Index	24/22/24	CI
Gemini Therapeutics, Inc.(NasdaqGM:GMTX) dropped from Russell 2000 Growth-Defensive Index	24/22/24	CI
Gemini Therapeutics, Inc.(NasdaqGM:GMTX) dropped from Russell 3000E Growth Index	24/22/24	CI
Gemini Therapeutics, Inc.(NasdaqGM:GMTX) dropped from Russell 3000E Index	24/22/24	CI
Gemini Therapeutics, Inc.(NasdaqGM:GMTX) dropped from Russell 3000 Growth Index	24/22/24	CI
Gemini Therapeutics, Inc.(NasdaqGM:GMTX) dropped from Russell Small Cap Comp Growth Index	24/22/24	CI
Gemini Therapeutics, Inc.(NasdaqGM:GMTX) dropped from Russell Small Cap Comp Value Index	24/22/24	CI
Gemini Therapeutics, Inc.(NasdaqGM:GMTX) dropped from Russell 2000 Value Index	24/22/24	CI

Chart GEMI THER

Duration

Period

More charts

Company Profile

Gemini Therapeutics, Inc., formerly FS Development Corp., is a clinical-stage precision medicine company. The Company is principally focused on developing novel therapeutic compounds to treat genetically defined, age-related macular degeneration (AMD). The Company's lead product candidate, GEM103, is a recombinant form of the human complement factor H protein (CFH) and is designed to address both complement hyperactivity and restore retinal health in patients with AMD. Its Pipeline of product candidate includes (adeno-associated virus) AAV-CFH, AAV-CFI, AAV-Ab, GEM104 and GEM307. Its AAV-CFH program is complementary to GEM103 program, as AAV-CFH to construct that express GEM103 continuously at a therapeutic level. Its pipeline is designed to develop treatments for genetically subpopulations of patients suffering from dry AMD and linked diseases. The Company do not own or operate manufacturing facilities for the production of clinical or commercial quantities of its product candidates.

Sector

More about the company